Eltrombopag (Promacta)

General information

Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Aplastic anemia
• Autoimmune thrombocytopenic purpura (ITP)

Patient drug information

• Eltrombopag (Promacta) package insert
• Eltrombopag (Promacta) patient drug information (UpToDate)

History of changes in FDA indication

• 11/20/2008: Initial FDA approval for treatment of "thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy."
• 11/19/2012: FDA approved for treatment of "thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy."
• 8/26/2014: FDA approved for "patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy."

Also known as

Revolade, SB-497115-GR.